Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

Inclusion Criteria:

- Be able to speak and read English

- Be able to provide informed consent

- Have been diagnosed with metastatic melanoma at age 18 years or older

- Have been treated with either single agent or combination checkpoint inhibitor

- Be at least 12 months since first dose of above named agents

- Received no other systemic therapy after initiation of immunotherapy (interval
radiation or surgery will be permitted based on review with primary treating medical
oncologist)

Exclusion Criteria:

- Patients with cognitive, visual, or motor impairment such that they cannot complete
the survey as assessed by the research or clinical team

- Patients who developed a subsequent cancer after starting on checkpoint inhibitor(s),
exclusive of non-melanoma superficial skin cancers

- Patients with clinical documentation of progressive disease on the most recent
assessment in the electronic medical record

- Patients with symptomatic progression but continue on immunotherapy

- Note: For any patients where the disease status is not clear, we will confirm
that the disease is either stable or responsive with their primary treating
medical oncologist